A detailed history of Ameriprise Financial Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 348,850 shares of HALO stock, worth $16.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
348,850
Previous 370,866 5.94%
Holding current value
$16.6 Million
Previous $19.4 Million 2.78%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$51.3 - $64.42 $1.13 Million - $1.42 Million
-22,016 Reduced 5.94%
348,850 $20 Million
Q2 2024

Aug 14, 2024

SELL
$37.81 - $52.4 $813,557 - $1.13 Million
-21,517 Reduced 5.48%
370,866 $19.4 Million
Q1 2024

May 15, 2024

SELL
$33.68 - $41.95 $2.44 Million - $3.04 Million
-72,524 Reduced 15.6%
392,383 $16 Million
Q4 2023

Feb 14, 2024

BUY
$33.32 - $42.1 $591,896 - $747,864
17,764 Added 3.97%
464,907 $17.2 Million
Q3 2023

Nov 14, 2023

SELL
$36.46 - $44.03 $769,816 - $929,649
-21,114 Reduced 4.51%
447,143 $17.1 Million
Q2 2023

Aug 14, 2023

SELL
$30.28 - $38.74 $1.53 Million - $1.96 Million
-50,612 Reduced 9.75%
468,257 $16.9 Million
Q1 2023

May 15, 2023

SELL
$32.86 - $55.7 $244,905 - $415,132
-7,453 Reduced 1.42%
518,869 $19.8 Million
Q4 2022

Feb 14, 2023

SELL
$40.06 - $59.44 $3.91 Million - $5.81 Million
-97,708 Reduced 15.66%
526,322 $29.9 Million
Q3 2022

Nov 14, 2022

SELL
$38.53 - $51.78 $189,567 - $254,757
-4,920 Reduced 0.78%
624,030 $24.7 Million
Q2 2022

Aug 15, 2022

SELL
$37.35 - $48.3 $1.26 Million - $1.63 Million
-33,688 Reduced 5.08%
628,950 $27.7 Million
Q1 2022

May 16, 2022

BUY
$31.97 - $41.06 $1.01 Million - $1.29 Million
31,511 Added 4.99%
662,638 $26.4 Million
Q4 2021

Feb 14, 2022

BUY
$31.82 - $40.75 $1.41 Million - $1.81 Million
44,462 Added 7.58%
631,127 $25.4 Million
Q3 2021

Nov 15, 2021

BUY
$38.47 - $46.42 $563,931 - $680,470
14,659 Added 2.56%
586,665 $23.9 Million
Q2 2021

Aug 16, 2021

SELL
$38.84 - $51.31 $862,481 - $1.14 Million
-22,206 Reduced 3.74%
572,006 $26 Million
Q1 2021

May 17, 2021

SELL
$39.51 - $51.45 $2.96 Million - $3.86 Million
-74,931 Reduced 11.2%
594,212 $24.8 Million
Q4 2020

Feb 12, 2021

BUY
$25.81 - $43.62 $6 Million - $10.1 Million
232,279 Added 53.17%
669,143 $28.6 Million
Q3 2020

Nov 16, 2020

SELL
$25.74 - $29.63 $44,427 - $51,141
-1,726 Reduced 0.39%
436,864 $11.5 Million
Q2 2020

Aug 14, 2020

BUY
$16.25 - $26.81 $484,786 - $799,822
29,833 Added 7.3%
438,590 $11.8 Million
Q1 2020

May 15, 2020

BUY
$13.9 - $21.83 $201,800 - $316,927
14,518 Added 3.68%
408,757 $7.35 Million
Q4 2019

Feb 14, 2020

SELL
$14.93 - $19.53 $176,517 - $230,903
-11,823 Reduced 2.91%
394,239 $6.99 Million
Q3 2019

Nov 14, 2019

SELL
$15.2 - $17.69 $4,940 - $5,749
-325 Reduced 0.08%
406,062 $6.3 Million
Q2 2019

Aug 14, 2019

BUY
$14.75 - $17.26 $2.33 Million - $2.72 Million
157,702 Added 63.41%
406,387 $6.98 Million
Q1 2019

May 15, 2019

SELL
$13.94 - $17.58 $28,423 - $35,845
-2,039 Reduced 0.81%
248,685 $4 Million
Q4 2018

Feb 14, 2019

BUY
$13.33 - $18.66 $260,708 - $364,952
19,558 Added 8.46%
250,724 $3.67 Million
Q3 2018

Nov 14, 2018

BUY
$16.68 - $18.41 $1.41 Million - $1.56 Million
84,702 Added 57.83%
231,166 $4.2 Million
Q2 2018

Aug 14, 2018

BUY
$16.87 - $20.3 $1,636 - $1,969
97 Added 0.07%
146,464 $2.47 Million
Q1 2018

May 15, 2018

BUY
$17.06 - $21.2 $670,730 - $833,499
39,316 Added 36.73%
146,367 $2.87 Million
Q4 2017

Feb 12, 2018

SELL
$16.75 - $20.8 $467,609 - $580,673
-27,917 Reduced 20.68%
107,051 $2.17 Million
Q3 2017

Nov 07, 2017

BUY
$11.76 - $17.4 $1.59 Million - $2.35 Million
134,968
134,968 $2.35 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.62B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.